CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Six-month ARV dispensingWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1721 Oxytocin Wiki 1.00
drug2319 Standard of Care Wiki 0.20

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D014777 Virus Diseases NIH 0.12
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Evaluation of the National Department of Health's Six-month Antiretroviral Treatment Dispensing Demonstration Pilot in Primary Health Care Clinics in the Context of the COVID-19 Pandemic and Response in South Africa

Many countries in sub-Saharan Africa are implementing a policy of six-month dispensing of antiretroviral (ARV) medications for HIV. Under the new guidelines, stable patients can receive a six-month supply of ARV medications at once, reducing the number of clinic visits required for medication refills. South Africa is considering this policy but has not yet adopted it and has requested evidence of its feasibility, effectiveness, and costs to the healthcare system and to patients. The decision on whether to implement a six-month dispensing policy has become urgent due to the SARS-Cov-2 epidemic, as clinic visits to refill prescriptions pose COVID-19 transmission risks to both patients and providers. To generate the required evidence, South Africa is implementing a pilot program that will allow for a cluster-randomized evaluation of 6-month dispensing. This protocol is for that evaluation. It aims to provide supporting evidence to inform future policy and procurement decisions by the National Department of Health (NDOH). All interventions will be conducted as part of routine care by Department of Health staff. In the pilot program, the NDOH will randomize 28 clinics in two provinces 1:1 to receive the six month dispensing intervention or continue standard of care, which currently allows for 2-3 month dispensing. The researchers will assess the patient outcomes of six month dispensing, administer a cross-sectional patient questionnaire, conduct semi-structured in-depth interviews with care providers and implementers, and estimate the costs to NDOH and to patients of six month dispensing. A maximum of 150,545 patients will be followed through their medical records and 400 patients and providers will be consented to be interviewed at baseline and after 6 months (total maximum sample size = 150,945).

NCT04468789 HIV Other: Six-month ARV dispensing

Primary Outcomes

Description: Proportion of patients eligible for 6 multi-month dispensing (6MMD) who enroll in 6MMD at intervention sites

Measure: Uptake of 6MMD

Time: Baseline

Description: Proportion of patients eligible for 6MMD who are retained in care at 6 months

Measure: Retention in care

Time: 6 months

Description: Proportion of patients eligible for 6MMD who are virally suppressed at 12 months

Measure: Viral suppression

Time: 12 months

Secondary Outcomes

Description: Acceptability of 6MMD to healthcare providers, based on interview responses

Measure: Provider acceptability of 6MMD before intervention

Time: Baseline

Description: Acceptability of 6MMD to healthcare providers, based on interview responses

Measure: Provider acceptability of 6MMD after intervention

Time: 6 months

Description: Acceptability of 6MMD to patients, based on survey responses

Measure: Patient acceptability at baseline

Time: Baseline

Description: Acceptability of 6MMD to patients, based on survey responses

Measure: Patient acceptability at 6 months

Time: 6 months

Description: Costs to healthcare provider (study clinics) of 6MMD, compared to standard of care

Measure: Provider costs

Time: 12-months


No related HPO nodes (Using clinical trials)